TruTumor Precision Therapeutics
​
Preserving native contextures in the human tumor microenvironment
Capturing the heterogeneity in tumor response and resistance ex-vivo
Simultaneously comparing multiple therapies for a single tumor
Generating predictive biosignatures to guide decision making through out clinical development of novel therapeutics
panCK CD8 CD3 CD68 Nucleus
Farcast proprietary image
Making Precision Cancer Medicine Work Better
Our mission is to make precision cancer medicine work better for patients. Because poor response rates of cancer therapies places a large burden on patients and health systems​
Perturbation of live Tumor Microenvironments (TME) with existing or under development cancer therapies and their combinations empowers the Farcast biodynamics system to predict response and estimate prognosis more accurately. The system's integration of multimodal signals from the TME and its peripheral components has the power to reshape response rates for cancer patients
​
Farcast has been a leader in TME research from inception at MIT in 2012 with experience of evaluating 25,000+ TMEs since. Through trusted relationships with network of global cancer centers for processing of multi-population tumor samples
FARCAST BIOSIGNATURES PREDICT CLINICAL RESPONSE
The Farcast technology system generates high quality, multimodal data from its advanced anthropic (true-to-human) systems to truly capture the complexity of tumor response and resistance to treatments. Treatment response and resistance “big data” are mined using the platform's AI capabilities to discover biosignatures with higher predictive power compared to simplistic biomarkers. Over 25,000 human tumors have been processed by the platform in multiple solid tumor types, across multiple mechanisms and diverse population cohorts.
